Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

Noots Focus Pills can enhance brain health, boost focus, and increase energy naturally. Achieve mental clarity and sustained energy today!

"The view out there in the analyst community is that the future of Biogen depends on the next deal that we do and that's not ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected. Click here to find out why ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

By 2060, 1 million adults per year will develop dementia, according to a study published in Nature Medicine. Also in the news, chronic cannabis use may lead to chronic illness; Eli Lilly hopes to ...